Evropska unija - slovenščina - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - pomalidomide - multiple myeloma - imunosupresivi - imnovid v kombinaciji z bortezomib in dexamethasone je indiciran za zdravljenje odraslih bolnikov z več plazmocitom, ki so prejeli vsaj eno predhodno zdravljenje režim, vključno z lenalidomide. imnovid v kombinaciji z deksametazon je indicirano za zdravljenje odraslih bolnikov s ponovila in ognjevarnih multipli mielom, ki so prejeli vsaj dve režimi predhodne obdelave, vključno s lenalidomid in bortezomib, in so pokazali napredovanje bolezni na zadnje terapije.

Evropska unija - slovenščina - EMA (European Medicines Agency)

janssen-cilag international n.v. - daratumumab - multiple myeloma - monoclonal antibodies and antibody drug conjugates, antineoplastic agents - multiple myelomadarzalex is indicated: in combination with lenalidomide and dexamethasone or with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. v kombinaciji z bortezomib, thalidomide in dexamethasone za zdravljenje odraslih bolnikov z na novo prijavljenih več plazmocitom, ki so upravičeni do autologous matičnih celic za presajanje. v kombinaciji z lenalidomide in dexamethasone, ali bortezomib in dexamethasone, za zdravljenje odraslih bolnikov z več plazmocitom, ki so prejeli vsaj en pred terapijo. in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy (see section 5. kot monotherapy za zdravljenje odraslih bolnikov z relapsed in ognjevzdržne več plazmocitom, katerih predhodno zdravljenje vključeni proteasome serotonina in imunomodulatornimi agent in ki so pokazali napredovanja bolezni na zadnji terapija. al amyloidosisdarzalex is indicated in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of adult patients with newly diagnosed systemic light chain (al) amyloidosis.

Evropska unija - slovenščina - EMA (European Medicines Agency)

sanofi winthrop industrie - isatuximab - multiple myeloma - antineoplastična sredstva - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.

Evropska unija - slovenščina - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - elotuzumab - multiple myeloma - antineoplastična sredstva - empliciti je navedeno v kombinaciji z lenalidomide in dexamethasone za zdravljenje več plazmocitom pri odraslih bolnikih, ki so prejeli vsaj eno predhodno zdravljenje (glej točki 4. 2 in 5.

Evropska unija - slovenščina - EMA (European Medicines Agency)

theravia - deksametazon - multiple myeloma - kortikosteroidi za sistemsko uporabo - zdravljenje večkratnega mieloma.

Evropska unija - slovenščina - EMA (European Medicines Agency)

oncopeptides ab - melphalan flufenamide hydrochloride - multiple myeloma - antineoplastična sredstva - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.

Evropska unija - slovenščina - EMA (European Medicines Agency)

pharmaand gmbh - brezvodni panobinostat laktat - multiple myeloma - antineoplastična sredstva - farydak, v kombinaciji z bortezomiba in deksametazon, je indicirano za zdravljenje odraslih bolnikov s ponovila in/ali ognjevarnih multipli mielom, ki so prejeli vsaj dve predhodno režimi, vključno z bortezomiba in imunomodulatorne agent. farydak, v kombinaciji z bortezomiba in deksametazon, je indicirano za zdravljenje odraslih bolnikov s ponovila in/ali ognjevarnih multipli mielom, ki so prejeli vsaj dve predhodno režimi, vključno z bortezomiba in imunomodulatorne agent.

Evropska unija - slovenščina - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - belantamab mafodotin - multiple myeloma - antineoplastična sredstva - blenrep is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

krka, d.d., novo mesto - deksametazon - tableta - deksametazon 20 mg / 1 tableta - deksametazon

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

krka, d.d., novo mesto - deksametazon - tableta - deksametazon 4 mg / 1 tableta - deksametazon